Thermo Fisher Scientific Inc. $TMO Shares Acquired by New Mexico Educational Retirement Board

New Mexico Educational Retirement Board grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,662 shares of the medical research company’s stock after purchasing an additional 900 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Thermo Fisher Scientific were worth $9,356,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. J. Stern & Co. LLP boosted its holdings in Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the period. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $15,501,867,000. State Street Corp raised its position in Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after purchasing an additional 229,630 shares in the last quarter. Corient Private Wealth LP purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $382,547,000. Finally, Capital World Investors grew its position in shares of Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 over the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $621.87 on Friday. The company has a market capitalization of $229.94 billion, a price-to-earnings ratio of 33.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a 50 day moving average price of $558.64 and a 200 day moving average price of $512.08.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter last year, the company earned $4.28 earnings per share. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMO. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.